flx-787
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2017 (NCT03196375)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- flx-787
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03334786 | Phase 1/Phase 2 (Phase 2) | Apr 5, 2018 | Flex Pharma, Inc. |
| NCT03338114 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2017 | Flex Pharma, Inc. |
| NCT03254199 | Phase 2 | Oct 16, 2017 | Flex Pharma, Inc., University of Utah |
| NCT03196375 | Phase 2 | Jun 30, 2017 | Flex Pharma, Inc., Mayo Clinic |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Flex Pharma, Inc. | For profit | 4 | 4 | 1 | 2017 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1